Clinical Trial Update: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating masupirdine for agitation in Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Masupirdine (Masupirdine)

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Agitation, Alzheimer's Type Dementia | Phase 3 | Status: RECRUITING